Journal of mood and anxiety disorders
December 1, 2023
Sierra Carter, Grace Packard, Callan Coghlan et al.
18 citations
Black Americans reported more positive views of psychedelic-assisted therapy than White Americans after receiving brief psychoeducation about MDMA and psilocybin-assisted therapy. Among 294 adults (44% Black/African American or Mixed Race with Black ancestry, 56% White American; average age 36.3 years), psychoeducation increased interest and positivity across both groups. Greater depression and PTSD symptom severity was linked to higher baseline interest in both groups, and Black participants with more severe depression showed even greater interest and more positive views. The findings suggest that research groups, not potential participants, are responsible for diversifying clinical trial samples and that rebuilding trust and providing culturally attuned interventions is needed.
Frontiers in Psychiatry
January 9, 2024
Terence H W Ching, Lucia Amoroso, Calvin Bohner et al.
9 citations
A randomized controlled trial will test whether two doses of psilocybin (25 mg followed by either 25 or 30 mg), given with non-directive support, reduce obsessive-compulsive disorder (OCD) symptoms more than a single dose or a waitlist control. Thirty adults with treatment-refractory OCD will be enrolled. OCD symptoms will be measured with the Yale-Brown Obsessive-Compulsive Scale – Second Edition by a blinded rater at baseline and after the second dosing week. Participants will be followed for up to 12 months. The trial also aims to identify psychological mechanisms that may explain psilocybin's effects on OCD.
Frontiers in Public Health
December 11, 2024
Amy Bartlett, Challian Christ, Bradford Martins et al.
8 citations
A scoping review of academic literature on the intersection of queer identity and psychedelics found only 18 relevant resources from over 30,000 initially captured, revealing that most existing literature stigmatizes and problematizes queer psychedelic use. The review highlights strong interest among queer populations in using psychedelics for healing and identity development, and emphasizes the need for clinicians to understand queer psychedelic experiences to provide safe, effective care. It recommends future research directions to better explore the meaningful overlap between psychedelics and queerness, aiming to center queer experiences as essential in psychedelic research and practice.
JAMA psychiatry
May 1, 2026
Amanda Jones, Jennifer Warner-Schmidt, Hannah Kwak et al.
6 citations
In a phase 2 randomized clinical trial, TSND-201 (methylone) reduced PTSD symptoms more than placebo in adults aged 18 to 65. Over 10 weeks, 65 participants received either TSND-201 or placebo in four weekly oral sessions. The drug group showed a significantly greater improvement in the primary measure of PTSD severity (CAPS-5) than placebo, with a difference of about 10 points. Secondary measures of PTSD-related distress, disability, and depression also improved more with the drug. Common side effects included headache, nausea, and increased blood pressure. The results suggest TSND-201 is a well-tolerated, rapid-acting treatment for PTSD.
Frontiers in Psychiatry
February 16, 2024
Terence H W Ching, Lucia Amoroso, Calvin Bohner et al.
correction
A correction notice addresses an error in a previously published article on psilocybin therapy for obsessive-compulsive disorder. The notice specifies that the original article's DOI is 10.3389/fpsyt.2023.1278823 and provides the necessary correction. No findings, methods, or results are presented in this text.